Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

This study is designed as a single arm pilot feasibility trial using an induction of 2-6 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy followed by 6 cycles of brentuximab vedotin (SGN-35) consolidation for previously untreated patients with stage I and II non-bulky Hodgkin Lymphoma (HL).

Feasibility will be determined by the percentage of patients who have no clinical evidence of HL, and achieve positron emission tomograph (PET) negative disease post brentuximab consolidation. We anticipate approximately 40 patients will be eligible across participating centers (including UNC, Mayo Clinic, and the UNC Cancer Network (UNCCN)) over a 2 year period. A future phase II study evaluating progression free survival (PFS) after ABVD followed by brentuximab vedotin will be considered feasible if ≥ 13 of 15 patients enrolled in this pilot trial become PET negative after brentuximab vedotin consolidation.

Inclusion criteria

• Previously untreated stage I or II non-bulky Hodgkin lymphoma

• No mediastinal mass >0.33 maximum intrathoracic diameter on chest x-ray (see Appendix B)
• No adenopathy ≥7.5 cm in its largest diameter
• Measurable disease as assessed by 2 dimensional measurement by CT (>2cm or 1.5 cm if 0.5 cm slices are used, as in spiral CT scan)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Age ≥18 years and ≤60 years of age
• Life expectancy of at least 3 months
• Adequate bone marrow function (without transfusion support within one week of screening) as demonstrated by:

• Hemoglobin ≥ 8 g/dL
• Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
• Platelet count ≥ 75,000/mm3
• Adequate hepatic and renal function as demonstrated by:

• Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)
• Total serum bilirubin ≤1.5 x ULN
• Serum creatinine ≤ 2.0 mg/dL
• Negative serum human chorionic gonadotropin (β-hCG) pregnancy test within 72 hours of day 1 of treatment with ABVD in women of child-bearing potential
• Females of childbearing potential, and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of brentuximab vedotin. Effective contraception is defined as any medically recommended method (or combination of methods) as per standard of care, including abstinence. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.
• Signed an institutional review board (IRB)-approved informed consent document for this protocol

Prior to Day 1 of brentuximab vedotin, patients must again meet the following inclusion criteria:

• Adequate bone marrow function (without transfusion support within one week of D1 of brentuximab vedotin) as demonstrated by:

• Hemoglobin ≥ 8 g/dL
• Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
• Platelet count ≥ 75,000/mm3
• Adequate hepatic and renal function as demonstrated by:

• Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)
• Total serum bilirubin ≤1.5 x ULN
• Serum creatinine ≤ 2.0 mg/dL
• Achieved at least a partial response (PR) (and not progressed) after ABVD therapy

Exclusion criteria

• Prior therapies for treatment of HL including involved field radiation therapy or any prior treatment for any malignancy with anthracyclines.
• Bulky disease (defined as a mass measuring > 7.5 cm or one-third the maximal diameter of the thoracic cavity)
• Known central nervous system (CNS) involvement
• Symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators
• Known history of human immunodeficiency virus (HIV), hepatitis B and hepatitis C (testing is not necessary if patient does not have history of these diseases, and no risk factors for acquisition of these viruses)
• Cardiac disease with left ventricular ejection fraction of less than 45%
• Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
• Medical or other condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective
• Other active malignancies with the exception of:

• Non-melanoma skin cancer
• Cervical carcinoma in situ without evidence of disease
• Prostatic intraepithelial neoplasia without evidence of prostate cancer
• Pregnant or lactating women

Prior to Day 1 of brentuximab vedotin, please verify the patient does not meet the criteria below:

• Symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators